| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 25 | 2023 | 66 | 6.480 |
Why?
|
| Rhinitis | 22 | 2023 | 59 | 5.140 |
Why?
|
| Endoscopy | 31 | 2023 | 83 | 4.620 |
Why?
|
| Paranasal Sinuses | 17 | 2022 | 30 | 4.180 |
Why?
|
| Paranasal Sinus Neoplasms | 10 | 2019 | 20 | 1.820 |
Why?
|
| Nasal Polyps | 6 | 2023 | 14 | 1.750 |
Why?
|
| Otolaryngology | 5 | 2020 | 14 | 1.560 |
Why?
|
| Humans | 70 | 2023 | 12240 | 1.480 |
Why?
|
| Skull Base | 7 | 2013 | 13 | 1.440 |
Why?
|
| Tomography, X-Ray Computed | 14 | 2018 | 281 | 1.380 |
Why?
|
| Middle Aged | 33 | 2021 | 4043 | 1.340 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 7 | 2019 | 12 | 1.330 |
Why?
|
| Papilloma, Inverted | 6 | 2015 | 6 | 1.320 |
Why?
|
| Chronic Disease | 20 | 2023 | 186 | 1.280 |
Why?
|
| Male | 38 | 2021 | 6815 | 1.170 |
Why?
|
| Retrospective Studies | 26 | 2023 | 1467 | 1.110 |
Why?
|
| Female | 40 | 2022 | 6974 | 1.110 |
Why?
|
| Rhinitis, Allergic | 2 | 2018 | 11 | 1.020 |
Why?
|
| Adult | 26 | 2021 | 3557 | 0.980 |
Why?
|
| Staphylococcal Infections | 3 | 2018 | 81 | 0.970 |
Why?
|
| Nose | 3 | 2018 | 13 | 0.950 |
Why?
|
| Epistaxis | 2 | 2020 | 9 | 0.940 |
Why?
|
| Nose Neoplasms | 4 | 2016 | 12 | 0.920 |
Why?
|
| Ethmoid Sinus | 3 | 2017 | 6 | 0.830 |
Why?
|
| Anti-Bacterial Agents | 3 | 2015 | 207 | 0.780 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2015 | 68 | 0.780 |
Why?
|
| Betacoronavirus | 2 | 2020 | 38 | 0.760 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 45 | 0.740 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 48 | 0.740 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 3 | 2010 | 3 | 0.720 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2015 | 70 | 0.720 |
Why?
|
| Catheterization | 2 | 2013 | 23 | 0.710 |
Why?
|
| Paranasal Sinus Diseases | 5 | 2010 | 6 | 0.690 |
Why?
|
| Microbiota | 2 | 2018 | 35 | 0.680 |
Why?
|
| Pseudomonas aeruginosa | 3 | 2018 | 17 | 0.670 |
Why?
|
| Surgery, Computer-Assisted | 5 | 2007 | 22 | 0.650 |
Why?
|
| Hemostatic Techniques | 1 | 2020 | 6 | 0.640 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2020 | 6 | 0.630 |
Why?
|
| Airway Management | 1 | 2020 | 12 | 0.630 |
Why?
|
| Urban Health Services | 1 | 2020 | 7 | 0.630 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 15 | 0.630 |
Why?
|
| Disease Management | 1 | 2020 | 59 | 0.610 |
Why?
|
| Aged | 18 | 2019 | 4000 | 0.610 |
Why?
|
| Telemedicine | 1 | 2020 | 45 | 0.590 |
Why?
|
| Treatment Outcome | 14 | 2022 | 1478 | 0.570 |
Why?
|
| Bacteroidetes | 1 | 2018 | 3 | 0.570 |
Why?
|
| Firmicutes | 1 | 2018 | 5 | 0.570 |
Why?
|
| Follow-Up Studies | 10 | 2015 | 726 | 0.560 |
Why?
|
| Neutrophils | 1 | 2018 | 58 | 0.550 |
Why?
|
| Eustachian Tube | 2 | 2019 | 2 | 0.540 |
Why?
|
| Rhinoplasty | 2 | 2022 | 9 | 0.530 |
Why?
|
| Pituitary Neoplasms | 1 | 2017 | 5 | 0.510 |
Why?
|
| Pituitary Gland | 1 | 2017 | 7 | 0.510 |
Why?
|
| Quality of Life | 5 | 2020 | 261 | 0.490 |
Why?
|
| Asthma | 2 | 2016 | 76 | 0.490 |
Why?
|
| Postoperative Complications | 3 | 2017 | 385 | 0.480 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 17 | 0.480 |
Why?
|
| Inflammation | 1 | 2017 | 124 | 0.480 |
Why?
|
| Young Adult | 6 | 2018 | 863 | 0.480 |
Why?
|
| Dacryocystorhinostomy | 1 | 2015 | 1 | 0.450 |
Why?
|
| Orbit | 1 | 2015 | 1 | 0.450 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2017 | 142 | 0.440 |
Why?
|
| Aged, 80 and over | 9 | 2018 | 2152 | 0.430 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 55 | 0.430 |
Why?
|
| Adolescent | 7 | 2018 | 989 | 0.420 |
Why?
|
| Otitis Externa | 1 | 2013 | 1 | 0.400 |
Why?
|
| Osteomyelitis | 1 | 2013 | 8 | 0.400 |
Why?
|
| Monitoring, Intraoperative | 2 | 2010 | 15 | 0.400 |
Why?
|
| Diabetes Complications | 1 | 2013 | 28 | 0.400 |
Why?
|
| Catheters | 1 | 2013 | 10 | 0.390 |
Why?
|
| Prospective Studies | 5 | 2017 | 817 | 0.380 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2012 | 2 | 0.380 |
Why?
|
| Cholesterol | 1 | 2012 | 30 | 0.370 |
Why?
|
| Staphylococcus aureus | 3 | 2018 | 36 | 0.360 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2012 | 8 | 0.360 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2012 | 26 | 0.350 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2011 | 1 | 0.330 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2011 | 1 | 0.330 |
Why?
|
| Fellowships and Scholarships | 1 | 2011 | 18 | 0.330 |
Why?
|
| Mycoses | 1 | 2011 | 14 | 0.330 |
Why?
|
| Acetazolamide | 1 | 2010 | 1 | 0.330 |
Why?
|
| Fluorescein | 1 | 2010 | 1 | 0.330 |
Why?
|
| Education, Medical, Graduate | 1 | 2011 | 37 | 0.330 |
Why?
|
| Child | 5 | 2021 | 614 | 0.330 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2010 | 6 | 0.330 |
Why?
|
| Fluorescent Dyes | 1 | 2010 | 24 | 0.320 |
Why?
|
| Anastomosis, Surgical | 1 | 2009 | 12 | 0.310 |
Why?
|
| Arteries | 1 | 2009 | 11 | 0.310 |
Why?
|
| Turbinates | 1 | 2009 | 2 | 0.300 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2009 | 3 | 0.300 |
Why?
|
| Clinical Competence | 3 | 2020 | 96 | 0.300 |
Why?
|
| Bone Resorption | 1 | 2009 | 55 | 0.290 |
Why?
|
| Disease Progression | 3 | 2018 | 290 | 0.270 |
Why?
|
| Radioallergosorbent Test | 1 | 2008 | 1 | 0.270 |
Why?
|
| Skin Tests | 1 | 2008 | 2 | 0.270 |
Why?
|
| Poaceae | 1 | 2008 | 3 | 0.270 |
Why?
|
| Allergens | 1 | 2008 | 10 | 0.270 |
Why?
|
| Hypersensitivity | 1 | 2008 | 20 | 0.270 |
Why?
|
| Frontal Sinus | 1 | 2007 | 3 | 0.260 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 423 | 0.260 |
Why?
|
| United States | 4 | 2019 | 989 | 0.260 |
Why?
|
| Postoperative Period | 2 | 2018 | 118 | 0.250 |
Why?
|
| Cadaver | 3 | 2013 | 166 | 0.240 |
Why?
|
| Meningioma | 2 | 2005 | 7 | 0.240 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 168 | 0.230 |
Why?
|
| Health Surveys | 2 | 2015 | 38 | 0.210 |
Why?
|
| Sphenoid Sinus | 5 | 2008 | 10 | 0.200 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 546 | 0.200 |
Why?
|
| Pseudomonas Infections | 2 | 2015 | 17 | 0.200 |
Why?
|
| Tracheostomy | 2 | 2020 | 9 | 0.200 |
Why?
|
| Diagnosis, Differential | 3 | 2018 | 151 | 0.200 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 53 | 0.190 |
Why?
|
| Survival Analysis | 2 | 2015 | 99 | 0.190 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 40 | 0.180 |
Why?
|
| Pandemics | 2 | 2020 | 126 | 0.180 |
Why?
|
| Cerebellar Neoplasms | 1 | 2002 | 1 | 0.180 |
Why?
|
| Cochlear Nerve | 1 | 2002 | 1 | 0.180 |
Why?
|
| Cerebellopontine Angle | 1 | 2002 | 2 | 0.180 |
Why?
|
| Nasal Cartilages | 1 | 2022 | 3 | 0.180 |
Why?
|
| Facial Nerve | 1 | 2002 | 7 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2015 | 464 | 0.180 |
Why?
|
| Radiology | 1 | 2021 | 8 | 0.170 |
Why?
|
| Encephalocele | 1 | 2021 | 6 | 0.170 |
Why?
|
| Hemoptysis | 1 | 2001 | 4 | 0.170 |
Why?
|
| Prognosis | 3 | 2019 | 363 | 0.170 |
Why?
|
| Air Pollutants | 1 | 2021 | 10 | 0.170 |
Why?
|
| Air Pollution | 1 | 2021 | 13 | 0.170 |
Why?
|
| Laryngopharyngeal Reflux | 1 | 2020 | 2 | 0.160 |
Why?
|
| Cryosurgery | 1 | 2020 | 12 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 14 | 0.160 |
Why?
|
| Simulation Training | 1 | 2020 | 15 | 0.160 |
Why?
|
| Emergencies | 1 | 2020 | 26 | 0.160 |
Why?
|
| Eosinophils | 1 | 2019 | 15 | 0.150 |
Why?
|
| Eosinophilia | 1 | 2019 | 13 | 0.150 |
Why?
|
| Ear Diseases | 1 | 2019 | 1 | 0.150 |
Why?
|
| Dilatation | 1 | 2019 | 3 | 0.150 |
Why?
|
| Nasal Cavity | 3 | 2016 | 12 | 0.150 |
Why?
|
| Insurance Coverage | 1 | 2019 | 7 | 0.140 |
Why?
|
| Melanoma | 1 | 2019 | 34 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 165 | 0.140 |
Why?
|
| Metaplasia | 1 | 2018 | 5 | 0.140 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2018 | 28 | 0.140 |
Why?
|
| Biodiversity | 1 | 2018 | 16 | 0.140 |
Why?
|
| Osteoblastoma | 1 | 2018 | 3 | 0.140 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2011 | 81 | 0.130 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2017 | 3 | 0.130 |
Why?
|
| Basement Membrane | 1 | 2017 | 5 | 0.130 |
Why?
|
| Fibrosis | 1 | 2017 | 15 | 0.130 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 78 | 0.130 |
Why?
|
| Edema | 1 | 2017 | 15 | 0.130 |
Why?
|
| Mucous Membrane | 1 | 2017 | 10 | 0.130 |
Why?
|
| Nose Diseases | 2 | 2006 | 2 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2016 | 46 | 0.120 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2016 | 4 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2016 | 115 | 0.120 |
Why?
|
| Consensus | 1 | 2016 | 47 | 0.120 |
Why?
|
| Prevalence | 1 | 2016 | 175 | 0.120 |
Why?
|
| Biomarkers | 1 | 2017 | 294 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 324 | 0.110 |
Why?
|
| Radiation Dosage | 1 | 2015 | 23 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2015 | 48 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 69 | 0.110 |
Why?
|
| Nebulizers and Vaporizers | 2 | 2005 | 16 | 0.110 |
Why?
|
| Survival Rate | 3 | 2019 | 152 | 0.100 |
Why?
|
| Debridement | 1 | 2013 | 31 | 0.100 |
Why?
|
| Ear, Middle | 1 | 2013 | 2 | 0.100 |
Why?
|
| Laryngoscopy | 1 | 2013 | 8 | 0.100 |
Why?
|
| Patient Selection | 2 | 2020 | 111 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2013 | 113 | 0.100 |
Why?
|
| Equipment Design | 2 | 2011 | 76 | 0.100 |
Why?
|
| Neurosurgery | 1 | 2013 | 18 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 143 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2010 | 66 | 0.090 |
Why?
|
| Stenotrophomonas maltophilia | 1 | 2012 | 1 | 0.090 |
Why?
|
| Sex Factors | 1 | 2012 | 229 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2010 | 295 | 0.090 |
Why?
|
| Age Factors | 1 | 2012 | 350 | 0.090 |
Why?
|
| Workload | 1 | 2011 | 12 | 0.080 |
Why?
|
| Career Choice | 1 | 2011 | 13 | 0.080 |
Why?
|
| Endoscopes | 1 | 2011 | 4 | 0.080 |
Why?
|
| Video-Assisted Surgery | 1 | 2011 | 2 | 0.080 |
Why?
|
| Intraoperative Care | 1 | 2011 | 23 | 0.080 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 2010 | 1 | 0.080 |
Why?
|
| Empty Sella Syndrome | 1 | 2010 | 3 | 0.080 |
Why?
|
| Intracranial Hypertension | 1 | 2010 | 3 | 0.080 |
Why?
|
| Injections, Spinal | 1 | 2010 | 16 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2011 | 87 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 2010 | 35 | 0.080 |
Why?
|
| Recurrence | 1 | 2010 | 126 | 0.080 |
Why?
|
| Pilot Projects | 1 | 2011 | 214 | 0.080 |
Why?
|
| Illinois | 2 | 2019 | 110 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 40 | 0.080 |
Why?
|
| Sensitivity and Specificity | 2 | 2008 | 252 | 0.080 |
Why?
|
| Rhinometry, Acoustic | 1 | 2009 | 1 | 0.080 |
Why?
|
| Rhinomanometry | 1 | 2009 | 1 | 0.080 |
Why?
|
| Algorithms | 1 | 2010 | 169 | 0.080 |
Why?
|
| Hypertrophy | 1 | 2009 | 10 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2010 | 57 | 0.080 |
Why?
|
| Preoperative Period | 2 | 2019 | 34 | 0.070 |
Why?
|
| Osteogenesis | 1 | 2009 | 84 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2017 | 320 | 0.070 |
Why?
|
| Back | 1 | 2008 | 1 | 0.070 |
Why?
|
| Ambrosia | 1 | 2008 | 1 | 0.070 |
Why?
|
| Phleum | 1 | 2008 | 1 | 0.070 |
Why?
|
| Arm | 1 | 2008 | 30 | 0.070 |
Why?
|
| Papillomavirus Infections | 1 | 2007 | 8 | 0.070 |
Why?
|
| Radiography | 2 | 2004 | 258 | 0.060 |
Why?
|
| Histoplasmosis | 1 | 2006 | 7 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 73 | 0.060 |
Why?
|
| Neuroendoscopy | 1 | 2005 | 2 | 0.060 |
Why?
|
| Skull Base Neoplasms | 1 | 2005 | 5 | 0.060 |
Why?
|
| Posture | 1 | 2005 | 20 | 0.060 |
Why?
|
| Carotid Artery, Internal | 1 | 2005 | 1 | 0.060 |
Why?
|
| Craniotomy | 1 | 2005 | 9 | 0.060 |
Why?
|
| Dexamethasone | 1 | 2005 | 22 | 0.060 |
Why?
|
| Carcinoma | 1 | 2005 | 34 | 0.060 |
Why?
|
| Equipment Contamination | 1 | 2005 | 5 | 0.050 |
Why?
|
| Gram-Positive Bacteria | 1 | 2005 | 7 | 0.050 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2004 | 10 | 0.050 |
Why?
|
| Animals | 1 | 2008 | 2092 | 0.050 |
Why?
|
| Nasal Septum | 1 | 2022 | 5 | 0.050 |
Why?
|
| Facial Nerve Diseases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2002 | 5 | 0.050 |
Why?
|
| Mometasone Furoate | 1 | 2022 | 4 | 0.040 |
Why?
|
| Logistic Models | 1 | 2022 | 196 | 0.040 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 2021 | 3 | 0.040 |
Why?
|
| Petrous Bone | 1 | 2021 | 3 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2001 | 12 | 0.040 |
Why?
|
| Bronchoscopy | 1 | 2001 | 14 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 14 | 0.040 |
Why?
|
| Particulate Matter | 1 | 2021 | 13 | 0.040 |
Why?
|
| Observer Variation | 1 | 2021 | 47 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 29 | 0.040 |
Why?
|
| Infant | 1 | 2001 | 277 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2019 | 35 | 0.040 |
Why?
|
| Smoking | 1 | 2020 | 84 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 256 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2019 | 11 | 0.040 |
Why?
|
| Nasal Mucosa | 1 | 2019 | 5 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2019 | 156 | 0.030 |
Why?
|
| Osteoma | 1 | 2018 | 3 | 0.030 |
Why?
|
| Fibroma, Ossifying | 1 | 2018 | 3 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 90 | 0.030 |
Why?
|
| Probability | 2 | 2005 | 45 | 0.030 |
Why?
|
| DNA Probes, HPV | 1 | 2007 | 1 | 0.020 |
Why?
|
| Microdissection | 1 | 2007 | 1 | 0.020 |
Why?
|
| Alphapapillomavirus | 1 | 2007 | 3 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 33 | 0.020 |
Why?
|
| Stereotaxic Techniques | 1 | 2006 | 6 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2006 | 17 | 0.020 |
Why?
|
| Electromagnetic Phenomena | 1 | 2006 | 1 | 0.020 |
Why?
|
| Surgical Equipment | 1 | 2006 | 2 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2006 | 18 | 0.020 |
Why?
|
| Bone Screws | 1 | 2006 | 59 | 0.010 |
Why?
|
| Titanium | 1 | 2006 | 99 | 0.010 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2005 | 4 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 10 | 0.010 |
Why?
|
| Administration, Intranasal | 1 | 2005 | 10 | 0.010 |
Why?
|
| Mucocele | 1 | 2005 | 1 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2005 | 7 | 0.010 |
Why?
|
| Subdural Effusion | 1 | 2005 | 5 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 84 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2005 | 43 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2005 | 125 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2005 | 42 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 179 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2005 | 35 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2005 | 100 | 0.010 |
Why?
|
| Sterilization | 1 | 2005 | 5 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 2005 | 9 | 0.010 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2005 | 26 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2005 | 117 | 0.010 |
Why?
|
| Materials Testing | 1 | 2005 | 70 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2004 | 11 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 56 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2004 | 171 | 0.010 |
Why?
|